Reviews of "Serum Sphingosine-1-Phosphate as Novel Prognostic and Predictive Biomarker for COVID-19 Severity and Morbidity and Its Implications in Clinical Management"

**Yoh Takuwa¹, Hideru Obinata², Markus Gräler³,
Georgios Grammatikos⁴**

¹Kanazawa University Graduate School of Medical Sciences: Kanazawa Daigaku Daigakuin Iyaku Hokengaku Sogo Kenkyuka Iyaku Hoken Gakuiki Igakurui, Physiology, Japan,

²Gunma University Graduate School of Medicine School of Medicine: Gunma Daigaku Daigakuin Igakukei Kenkyuka Igakubu, Education and Research Support Center, Japan,

³Jena University Hospital: Universitätsklinikum Jena, Anaesthesiology and Intensive Care Medicine, Germany,

⁴Goethe University Frankfurt: Goethe-Universität Frankfurt am Main, Gastroenterology, Greece

Published on: Jan 11, 2021

DOI: 10.1162/2e3983f5.b3e46890

License: [Creative Commons Attribution 4.0 International License \(CC-BY 4.0\)](https://creativecommons.org/licenses/by/4.0/)

To read the original manuscript, click the link above.

Summary of Reviews: *This potentially informative article with some methodological flaws suggests that serum Sphingosine-1-Phosphate (S1P) is associated with COVID-19 severity. Further research is needed to understand if serum S1P could be provided therapeutically to reduce COVID-19 severity.*

Reviewer 1 (Yoh Takuwa) | ☐ ☐ ☐ ☐

Reviewer 2 (Hideru Obinata) | ☐ ☐ ☐ ☐

Reviewer 3 (Markus Gräler) | ☐ ☐ ☐ ☐

Reviewer 4 (Georgios Grammatikos) | ☐ ☐ ☐ ☐

RR:C19 Strength of [Evidence Scale Key](#)

☐ ☐ ☐ ☐ = Misleading

☐ ☐ ☐ ☐ = Not Informative

☐ ☐ ☐ ☐ = Potentially Informative

☐ ☐ ☐ ☐ ☐ = Reliable

☐ ☐ ☐ ☐ ☐ ☐ = Strong

To read the reviews, click the links below.